Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. Waldmann TA J Clin Immunol. 2007 Jan; 27(1):1-18. Epub 2007 Jan 11. PMID: 17216565. Abstract CommentRecommendBookmarkWatch